Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79849.960.6089%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Niagen Bioscience Inc

NAGENASDAQ
Trade with Public
Trade with Public
$3.17
0.061.93%
At close: Sep 4, 5:00 PM EST
$3.17
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Niagen Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Niagen Bioscience (NAGE).

Price Target Range — 6 Quarters

Analyst Consensus — 3 Analysts

3Buy
Consensus RatingBuy# Analysts3Avg. Consensus PT$15Upside to Avg. PT+362.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 11, 2026HC Wainwright & Co.Raghuram SelvarajuPT CutBuy$12→$11
May 5, 2026Canaccord GenuitySusan AndersonPT CutBuy$13→$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $12 to $11.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Niagen Bioscience, Lowers Price Target to $14

Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and lowers the price target from $16 to $14.
Benzinga Newsdesk

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

Benzinga Insights

PRO
HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Raises Price Target to $12

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and raises the price target from $11 to $12.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Niagen Bioscience, Raises Price Target to $16

Canaccord Genuity analyst Susan Anderson maintains Niagen Bioscience (NASDAQ:NAGE) with a Buy and raises the price target from $13 to $16.
Benzinga Newsdesk

What 4 Analyst Ratings Have To Say About Niagen Bioscience

Benzinga Insights

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved